Edward E. Partridge

13.5k total citations · 1 hit paper
195 papers, 9.9k citations indexed

About

Edward E. Partridge is a scholar working on Oncology, Reproductive Medicine and Epidemiology. According to data from OpenAlex, Edward E. Partridge has authored 195 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 54 papers in Reproductive Medicine and 50 papers in Epidemiology. Recurrent topics in Edward E. Partridge's work include Ovarian cancer diagnosis and treatment (51 papers), Cervical Cancer and HPV Research (45 papers) and Endometrial and Cervical Cancer Treatments (39 papers). Edward E. Partridge is often cited by papers focused on Ovarian cancer diagnosis and treatment (51 papers), Cervical Cancer and HPV Research (45 papers) and Endometrial and Cervical Cancer Treatments (39 papers). Edward E. Partridge collaborates with scholars based in United States, Belgium and Chile. Edward E. Partridge's co-authors include Mark F. Brady, Daniel L. Clarke‐Pearson, Katherine Y. Look, William J. Hoskins, William P. McGuire, Paul R. Kucera, Martin Davidson, Ronald D. Alvarez, Hugh M. Shingleton and Larry C. Kilgore and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Biological Chemistry.

In The Last Decade

Edward E. Partridge

192 papers receiving 9.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

1996 2.3k citations William P. McGuire, William J. Hoskins et al. profile →

Peers

Countries citing papers authored by Edward E. Partridge

Since Specialization

Citations

This map shows the geographic impact of Edward E. Partridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward E. Partridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward E. Partridge more than expected).

Fields of papers citing papers by Edward E. Partridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward E. Partridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward E. Partridge. The network helps show where Edward E. Partridge may publish in the future.

Co-authorship network of co-authors of Edward E. Partridge

This figure shows the co-authorship network connecting the top 25 collaborators of Edward E. Partridge. A scholar is included among the top collaborators of Edward E. Partridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward E. Partridge. Edward E. Partridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implementation and Impact of Lay Navigator-Led Advance Care Planning for Cancer Patients (FR440C) 2017 ·Journal of Pain and Symptom Management ·Gabrielle B. Rocque, J. Nicholas Dionne‐Odom, Courtney Williams, Bradford E. Jackson, Richard A. Taylor, Maria Pisu, Edward E. Partridge, Elizabeth Kvale, Chao‐Hui Huang, Soumya J. Niranjan, Karina I. Halilova, Kelly Kenzik, Linda Briggs	2
2	Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States 2017 ·PLoS ONE ·Wonsuk Yoo, Sangmi Kim, Warner K. Huh, Sarah Dilley, Steven S. Coughlin, Edward E. Partridge, Yunmi Chung, (unknown), Jae Kwan Lee, Sejong Bae	138
3	Assessing the Risk of Ovarian Malignancy in Asymptomatic Women With Abnormal CA 125 and Transvaginal Ultrasound Scans in the Prostate, Lung, Colorectal, and Ovarian Screening Trial 2013 ·Obstetrics and Gynecology ·Edward E. Partridge, Robert T. Greenlee, Thomas L. Riley, John Commins, Lawrence R. Ragard, (unknown), Saundra S. Buys, Philip C. Prorok, Mona N. Fouad	21
4	Predictors of Long-Term Outcome from Intraperitoneal Radioimmunotherapy for Ovarian Cancer 2012 ·Cancer Biotherapy and Radiopharmaceuticals ·Ruby F. Meredith, Zhiying You, Ronald D. Alvarez, Edward E. Partridge, William E. Grizzle, Albert F. LoBuglio	11
5	Patient navigation pilot project: results from the Community Health Advisors in Action Program (CHAAP). 2010 ·PubMed ·Mona N. Fouad, Theresa A. Wynn, Michelle Y. Martin, Edward E. Partridge	21
6	Prevalence, Incidence, and Natural History of Simple Ovarian Cysts Among Women >55 Years Old in a Large Cancer Screening Trial 2010 ·Obstetrical & Gynecological Survey ·Robert T. Greenlee, Bruce Kessel, Craig Williams, Thomas L. Riley, Lawrence R. Ragard, Patricia Hartge, Saundra S. Buys, Edward E. Partridge, Douglas J. Reding	1
7	Results from Four Rounds of Ovarian Cancer Screening in a Randomized Trial 2009 ·Obstetrical & Gynecological Survey ·Edward E. Partridge, Aimée R. Kreimer, Robert T. Greenlee, Craig Williams, (unknown), Timothy R. Church, Bruce Kessel, Christine Cole Johnson, Joel L. Weissfeld, Claudine Isaacs, Gerald L. Andriole, Sheryl Ogden, Lawrence R. Ragard, Saundra S. Buys	12
8	A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy 2006 ·Gynecologic Oncology ·Whitney A. Spannuth, Charles A. Leath, Warner K. Huh, Mack N. Barnes, Susan A. Davidson, Larry C. Kilgore, Edward E. Partridge, J.Maxwell Austin, Ronald D. Alvarez	17
9	Addressing Disparities through Coalition Building: Alabama REACH 2010 Lessons Learned 2006 ·Journal of Health Care for the Poor and Underserved ·Theresa A. Wynn, Rhoda E. Johnson, Mona N. Fouad, Cheryl L. Holt, Isabel C. Scarinci, (unknown), Edward E. Partridge, Mark Dignan, Sharina D. Person, Groesbeck P. Parham	20
10	Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women 2005 ·Cancer ·Isam A. Eltoum, David C. Chhieng, Janie Roberson, (unknown), Edward E. Partridge	23
11	Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent 2005 ·Gynecologic Oncology ·Mack N. Barnes, David Chhieng, (unknown), Jennifer L. Jones, William E. Grizzle, (unknown), Lynya Talley, Edward E. Partridge	7
12	Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3 2004 ·International Journal of Cancer ·Olga L. Henao, Chandrika J. Piyathilake, John W. Waterbor, Ellen Funkhouser, Gary L. Johanning, Douglas C. Heimburger, Edward E. Partridge	30
13	Human Papillomavirus Triage of Patients with Atypical Squamous Cells of Undetermined Significance on Cervical Papanicolaou Smear 2003 ·Annals of the Academy of Medicine Singapore ·Tyler O. Kirby, Warner K. Huh, Edward E. Partridge	1
14	Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. 2002 ·PubMed ·Cristina Rodríguez-Burford, Mack N. Barnes, Denise K. Oelschlager, Russell B. Myers, Lynya Talley, Edward E. Partridge, William E. Grizzle	85
15	Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I Study 2001 ·Cancer Biotherapy and Radiopharmaceuticals ·Ruby F. Meredith, Ronald D. Alvarez, Edward E. Partridge, M.B. Khazaeli, Chin-Yu Lin, Daniel J. Macey, J.Maxwell Austin, Larry C. Kilgore, William E. Grizzle, Jeffrey Schlom, Albert F. LoBuglio	70
16	Rectal Immunization for Induction of Specific Antibody in the Genital Tract of Women 1997 ·Journal of Clinical Immunology ·Peggy A. Crowley‐Nowick, Maria C. Bell, (unknown), Robert P. Edwards, (unknown), Edward E. Partridge, Jiří Městecký	47
17	Cyclophosphamide and Cisplatin Compared With Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer 1996 ·Obstetrical & Gynecological Survey ·William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke‐Pearson, Martin Davidson	38
18	Second-look laparotomy and salvage therapy: A research modality only? 1992 ·Gynecologic Oncology ·M. Potter, Kenneth D. Hatch, Seng-Jaw Soong, Edward E. Partridge, J.Maxwell Austin, Hugh M. Shingleton	33
19	Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits 1989 ·Gynecologic Oncology ·M. Potter, Edward E. Partridge, Hugh M. Shingleton, Seng-Jaw Soong, Robert Y. Kim, Kenneth D. Hatch, J.Maxwell Austin	20
20	Perioperative influences on infectious morbidity in radical hysterectomy 1981 ·Gynecologic Oncology ·William J. Mann, James W. Orr, Hugh M. Shingleton, J.Max Austin, Kenneth D. Hatch, Peyton T. Taylor, Edward E. Partridge, Seng-Jaw Soong	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact